Coexpression of glucagon-like peptide-1 (GLP-1) receptor, vasopressin, and oxytocin mRNAs in neurons of the rat hypothalamic supraoptic and paraventricular nuclei: effect of GLP-1(7-36)amide on vasopressin and oxytocin release.
J A Zueco, A I Esquifino, J A Chowen, E Alvarez, P O Castrillón, E Blázquez
文献索引:J. Neurochem. 72(1) , 10-6, (1999)
全文:HTML全文
摘要
This study was designed to gain better insight into the relationship between glucagon-like peptide-1 (GLP-1) (7-36) amide and vasopressin (AVP) and oxytocin (OX). In situ hybridization histochemistry revealed colocalization of the mRNAs for GLP-1 receptor, AVP, and OX in neurons of the hypothalamic supraoptic and paraventricular nuclei. To determine whether GLP-1(7-36)amide alters AVP and/or OX release, both in vivo and in vitro experimental study designs were used. In vivo, intravenous administration of 1 microg of GLP-1(7-36)amide into the jugular vein significantly decreased plasma AVP and OX concentrations. In vitro incubation of the neurohypophysis with either 0.1 or 1 microg of GLP-1(7-36)amide did not modify the release of AVP. However, addition of 1 microg of GLP-1(7-36)amide to the incubation medium increased slightly the secretion of OX. The coexpression of GLP-1 receptor and AVP mRNAs in hypothalamic supraoptic and paraventricular nuclei gives further support to the already reported central effects of GLP-1 (7-36)amide on AVP. Our findings also suggest a dual secretory response of AVP and OX to the effect of GLP-1 (7-36)amide, which most likely is related to the amount and/or the route of peptide administration.
相关化合物
相关文献:
2004-02-01
[Metab. Clin. Exp. 53(2) , 252-9, (2004)]
1997-10-01
[Clin. Sci. 93(4) , 343-7, (1997)]
2004-04-15
[J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 803(1) , 91-9, (2004)]
1998-06-01
[Physiol. Behav. 64(3) , 367-72, (1998)]
2005-06-01
[Pharmacology 74(3) , 119-26, (2005)]